Amblyopia is a common condition in children causing poor vision in one eye. It can be due to problems like anisometropia (unequal focus) or strabismus (misaligned eyes). People with amblyopia might struggle with focusing, reading, and seeing 3D images. Luminopia is a new, FDA-approved treatment for amblyopia that works in a special way by showing different images to each eye to improve vision. Since November 2022, many patients have started using it. This study aims to collect data on how well Luminopia works in everyday life. A special board called the IRB will oversee the study to ensure safety and accuracy.

• The study includes patients with amblyopia who have used Luminopia for at least 12 weeks.
• People who have been in other Luminopia trials can’t join this study.
• This study helps gather important information about Luminopia's real-world effectiveness.